安图生物主营业务为体外诊断试剂及仪器的研发、制造、整合及服务，产品涵盖免疫、微生物、生化、分子、凝血等检测领域。公司财务总监冯超姐告诉财联社记者，公司Q3自产体外诊断检测试剂收入约9.15亿元，体外诊断检测仪器收入约7850万元。①At the earnings conference, the director of Autobio Diagnostics stated that the increase in research and development expenses led to a decline in Q3 net income attributable to shareholders; ②The chairman of Autobio Diagnostics, Miao Yongjun, stated to investors that the molecular sector is expected to maintain a high-speed growth status, while the microbiology sector will maintain a stable growth of 15%-20% annually.
Financial Association News November 25th (Reporter He Fan) - "The molecular sector of the company is expected to maintain a high-speed growth status, while the microbiology sector will maintain a stable growth of 15%-20% annually." Miao Yongjun, the chairman of Autobio Diagnostics (603658.SH), made this statement to investors during the company's 2024 third-quarter earnings briefing today.
Regarding the progress and goals of the fully automated chemistry analyzer A6000 that investors are concerned about, Miao Yongjun stated, "The company's annual installation target for A6000 is 700 units, with 525 units installed in the first three quarters."
Autobio Diagnostics' main business is the research and development, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, covering the fields of immunology, microbiology, biochemistry, molecular, and coagulation testing. The company's Chief Financial Officer, Feng Chaojie, told Financial Association News reporters that the company's self-produced in vitro diagnostic test reagent revenue in Q3 was about 0.915 billion yuan, and the revenue from in vitro diagnostic testing instruments was about 78.5 million yuan.
In terms of the overall solution business for medical laboratory fully automated production lines, the secretary of the board of directors, Fang Ruikuan, stated that in the first three quarters, the installation progress of the X1 production line series met the company's expectations, while the installation progress of the B1 production line series fell below the expected target. As of the first half of this year, Autobio Diagnostics' intelligent laboratories have been established in 34 medical institutions nationwide.
The financial report shows that in the third quarter of this year, the company achieved revenue of 1.173 billion yuan, an increase of 3.38% year-on-year; net income attributable to shareholders was 0.337 billion yuan, a decrease of 5.18% year-on-year. Fang Ruikuan stated that the company's overseas sales revenue in the third quarter was about 69.7 million yuan, an increase of about 18.7% year-on-year; the decline in third-quarter performance was mainly due to the significant increase in research and development expenses, and the fourth quarter will still depend on expense spending.
In terms of expenses, the company's research and development expenses continued to rise to 0.511 billion yuan in the first three quarters, an increase of 10.61% year-on-year; consequently, the company's investment in research and development expenses reached 0.178 billion yuan in Q3.
In addition, the business dispute of the company's subsidiary, Yunnan Autu Jihe, is also one of the concerns of investors. Fang Ruikuan told Financial Association News reporters that the company is actively handling the relevant disputes and is expected to resolve them properly in the near future.
On October 16, Autobio Diagnostics announced that its secondary subsidiary Yunnan Autobio Jiuhet had a business dispute with Jinzan High Trading Company, the latter applied for pre-litigation property preservation. On October 15, Yunnan Autobio Jiuhet received a Civil Ruling issued by the Wuhua District People's Court of Kunming City, Yunnan Province, with some of its bank accounts being judicially frozen, with a frozen amount of 1.2957 million yuan.